Publications en collaboration avec des chercheurs de Ghent University (46)

2024

  1. Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM

    Intensive Care Medicine

2023

  1. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    European Urology

  2. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    European Journal of Cancer

  3. Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification

    Mayo Clinic Proceedings

  4. Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification

    Kidney International, Vol. 104, Núm. 6, pp. 1092-1102

2022

  1. A Systematic Review of the Current Evidence from Randomised Controlled Trials on the Impact of Medication Optimisation or Pharmacological Interventions on Quantitative Measures of Cognitive Function in Geriatric Patients

    Drugs and Aging, Vol. 39, Núm. 11, pp. 863-874

  2. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

    ESMO Open, Vol. 7, Núm. 5

  3. Poor timing and failure of source control are risk factors for mortality in critically ill patients with secondary peritonitis

    Intensive Care Medicine, Vol. 48, Núm. 11, pp. 1593-1606

2021

  1. Correction to: Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials (European Journal of Clinical Pharmacology, (2021), 77, 1, (1-12), 10.1007/s00228-020-02951-8)

    European Journal of Clinical Pharmacology

  2. Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials

    European Journal of Clinical Pharmacology, Vol. 77, Núm. 1

  3. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

    Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 1, pp. 60-71

  4. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 18, pp. 1959-1970

  5. Management of anaphylaxis due to COVID-19 vaccines in the elderly

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 10, pp. 2952-2964

  6. The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort

    Swiss medical weekly, Vol. 151, pp. w20528

2020

  1. Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

    Atherosclerosis

  2. Erratum to “2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

    Atherosclerosis

  3. Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study

    Rheumatology (United Kingdom), Vol. 59, Núm. 7, pp. 1684-1694

  4. Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1

    Science Translational Medicine, Vol. 12, Núm. 542

2019

  1. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

    Atherosclerosis, Vol. 290, pp. 140-205

  2. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2109-2119